Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide vs Infliximab in Pediatric Crohn's Disease
NCT03221166Phase 3Terminated
- Sponsor
- IRCCS Burlo Garofolo
- Start
- Feb 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of thalidomide in Crohn's disease, sponsored by IRCCS Burlo Garofolo. Primary endpoint: Efficacy in inducing mucosal healing at 52 weeks. Started Feb 2018; status: terminated.
02
Drugs
thalidomide
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03221166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03221166.